Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: big run who wrote (51044)	2/1/2000 6:01:00 PM
From: out_of_the_loop	Respond to of 122087

Last post here - rest can go to the GUMM thread. I am well-acquainted with Quigley and so is GumTech. Quigley was a one-product company with no other possibilities. The second studies did show efficacy of cold-eze to the extent that the first did. Cold-eze did not work on children. COld-eze was copyable because people marketed their copies as food supplements. None of this is true with Zicam. Again, GumTech's nicotine gum will be even more profitable than Zicam. I do not mean disrespect, but there are almost no similarities to Quigley, all the way from the several product lines (vs 1 for QGLY) to Guy Quigley's fleet of Rolls Royces and $2 million dollar salary (vs. much more reasonable salaries and options for GumTEch execs). Also, insiders are buying. I have researched Gum Tech for months, its markets, its competitors, its executives, its plant, etc., etc., so if you think it is ok to short on the basis of what you say, go ahead. That is what Wexler did when he did 3 minutes of DD (his own admission) and called it a fraud at 12 bucks and change. Also do some research into who is buying GUmTech and who their partner in nicotine is. Swedish Match gave them $10 million bucks to fund the joint venture, and Gum Tech gets 49% of the profits. GumTEch already spent over $1 million last year in new warehousing and manufacturing equipment to accommodate nicotine gum so they are just getting some of their costs back. GumTech also is negotiating with 2 of the largest toothpaste manufacturers (household names that start with C) to manufacture for them their dental gum. GumTech has the rights to the only material that can reduce plaque around 35%. I am not perfect and have certainly made some investing mistakes in the past and will do so in the future, but GumTech is not a mistake - it is a low float, highly shorted growth phase company that is just starting to be recognized. It will not be as thinly traded in the future and institutions are indeed buying it. Zicam is indeed selling well and one can, if one wants to do a bit of work, do some checking to find out. Again, I am happy to discuss GumTech on the GUMM thread and wish you well, but think that an informed decision, long or short, is the best personal policy. If you really think GumTech is just like Quigley, I would advise you to think about defining your time frame for your shortsale.